Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Iovance Biotherapeutics (IOVA) over the last 12 years, with Q3 2025 value amounting to $142.7 million.

  • Iovance Biotherapeutics' Short-term Investments changed N/A to $142.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $142.7 million, marking a year-over-year change of. This contributed to the annual value of $208.1 million for FY2024, which is 2612.94% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Short-term Investments stood at $142.7 million for Q3 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Short-term Investments peaked at $222.0 million during Q1 2024, and registered a low of $20.9 million during Q2 2023.
  • In the last 3 years, Iovance Biotherapeutics' Short-term Investments had a median value of $165.0 million in 2023 and averaged $143.5 million.
  • In the last 5 years, Iovance Biotherapeutics' Short-term Investments soared by 16809.85% in 2024 and then plummeted by 1529.77% in 2025.
  • Iovance Biotherapeutics' Short-term Investments (Quarter) stood at $165.0 million in 2023, then rose by 26.13% to $208.1 million in 2024, then tumbled by 31.42% to $142.7 million in 2025.
  • Its last three reported values are $142.7 million in Q3 2025, $168.7 million for Q2 2025, and $188.0 million during Q1 2025.